EKSO Bionics Files Routine 8-K, Confirms Nasdaq Listing

TL;DR

**EKSO filed a routine 8-K, no new news, just standard compliance.**

AI Summary

Ekso Bionics Holdings, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 10, 2024. This filing is a routine update to the SEC, primarily confirming the company's registration details, including its Common Stock trading on the Nasdaq Capital Market under the symbol EKSO. For investors, this filing is a standard compliance document and does not contain new financial or operational news that would immediately impact the stock price, indicating business as usual.

Why It Matters

This filing is a standard compliance update, confirming Ekso Bionics' registration details and its listing on the Nasdaq Capital Market, which is important for maintaining investor confidence and market access.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not disclose any new risks or material changes to the company's operations or financial health.

Analyst Insight

A smart investor would recognize this as a routine compliance filing with no immediate impact on the company's valuation or operational outlook, thus requiring no immediate action based solely on this document.

Key Numbers

• $0.001 — par value per share (par value of Ekso Bionics Holdings, Inc.'s Common Stock)

Key Players & Entities

• Ekso Bionics Holdings, Inc. (company) — registrant
• Nasdaq Capital Market (company) — exchange where Common Stock is registered
• January 10, 2024 (date) — date of earliest event reported
• January 16, 2024 (date) — filing date of the 8-K
• EKSO (company) — trading symbol
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Ekso Bionics Holdings, Inc. will continue to trade on the Nasdaq Capital Market. (Ekso Bionics Holdings, Inc.) — high confidence, target: 2025-01-16

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capi
• $1.55 — the "Offering") at an offering price of $1.55 per share. The Offering closed on
• $4.0 million — g are expected to be approximately $4.0 million after deducting placement agent fe
• $60,000 — eds in the Offering and reimbursed $60,000 of the Placement Agent's out-of-pocket
• $10,000 — out-of-pocket legal expenses as well as $10,000 of non-accountable expenses of the Plac
• $3.52 — 2019 Warrants had an exercise price of $3.52 per share. The May 2019 Warrants includ

Filing Documents

• ekso20240111_8k.htm (8-K) — 35KB
• ex_614848.htm (EX-5.1) — 14KB
• ex_614781.htm (EX-99.1) — 166KB
• 0001437749-24-001348.txt ( ) — 389KB
• ekso-20240110.xsd (EX-101.SCH) — 3KB
• ekso-20240110_def.xml (EX-101.DEF) — 11KB
• ekso-20240110_lab.xml (EX-101.LAB) — 15KB
• ekso-20240110_pre.xml (EX-101.PRE) — 11KB
• ekso20240111_8k_htm.xml (XML) — 3KB

01           Other Events

Item 8.01           Other Events   On January 10, 2024, Ekso Bionics Holdings, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of 2,967,742 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), in a registered direct offering (the "Offering") at an offering price of $1.55 per share. The Offering closed on or about January 16, 2024, subject to satisfaction of customary closing conditions.   The net proceeds of the Offering are expected to be approximately $4.0 million after deducting placement agent fees and expenses and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes, which may include research and development activities, selling, general and administrative costs, strategic initiatives and to meet working capital needs.   The Shares were offered pursuant to the Company's effective registration statement on Form S-3 and accompanying base prospectus (File No. 333-272607), previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). The Company filed a prospectus supplement with the SEC in connection with the sale of the Shares.   A.G.P./Alliance Global Partners (the "Placement Agent") acted as the exclusive placement agent for the Offering. The Company paid the Placement Agent a placement agent fee in an amount equal to seven percent (7%) of the aggregate gross proceeds in the Offering and reimbursed $60,000 of the Placement Agent's out-of-pocket legal expenses as well as $10,000 of non-accountable expenses of the Placement Agent.   The Purchase Agreement contains customary representations, wa

01           Financial Statements and Exhibits

Item 9.01           Financial Statements and Exhibits   (d) Exhibits     Exhibit Description         5.1 Opinion of Snell & Wilmer L.L.P.         23.1 Consent of Snell & Wilmer L.L.P. (included in the opinion of Snell & Wilmer L.L.P. filed as Exhibit 5.1 hereto)         99.1* Form of Securities Purchase Agreement, dated January 10, 2024, by and among the Company and the Purchasers thereto         104 Cover Page Interactive Data File (embedded within the Inline XBRL document)   *          Exhibits and schedules have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K and will be furnished to the Securities and Exchange Commission upon request.         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       EKSO BIONICS HOLDINGS, INC.   By: /s/  Jerome Wong   Name: Jerome Wong   Title: Chief Financial Officer             Dated: January 16, 2024    

View Full Filing

View this 8-K filing on SEC EDGAR